Ipamorelin: what the science actually shows about the selective GH secretagogue

Ipamorelin is a synthetic pentapeptide. Five amino acids, molecular weight around 711 daltons, sequence Aib-His-D-2-Nal-D-Phe-Lys-NH₂ ^[1]. The original code name in the Novo Nordisk lab notebooks was NNC 26-0161 ^[2]. It belongs to a class called growth hormone secretagogues, or GHSs, compounds that prompt the anterior pituitary to release growth hormone on its own schedule rather than introducing exogenous GH.

The hook, when Kjeld Raun and colleagues published the original characterization in 1998, was selectivity ^[3]. Earlier GHSs in the same family, GHRP-2 and GHRP-6, worked, but they also drove cortisol, ACTH, and prolactin upward as a side effect. Ipamorelin, in conscious swine, released GH at doses up to 200 times the ED₅₀ for GH release without statistically real elevation of any of those off-target hormones ^[4].

That was the finding that earned it a decade of research attention. Whether it has earned the marketing built on top of it is a different question.

The receptor is GHSR-1a, the growth hormone secretagogue receptor, subtype 1a. It's a G-protein-coupled receptor sitting on somatotroph cells in the anterior pituitary, the same receptor that endogenous ghrelin binds when your stomach signals hunger.

When ipamorelin docks at GHSR-1a, the cell mobilizes intracellular calcium and activates protein kinase C signaling cascades ^[5]. The downstream effect is pulsatile GH release, a burst rather than a flood. Peak GH appears at roughly 40 minutes post-administration in human dose-escalation data, then declines exponentially toward baseline ^[6]. Estimated half-life is about two hours ^[7].

That pulsatility matters more than it sounds. Endogenous GH doesn't pour out continuously. It surges in pulses, mostly at night, governed by a feedback loop between hypothalamic GHRH and somatostatin. Ipamorelin works with that architecture rather than overriding it. Exogenous recombinant GH, by contrast, floods the system on whatever schedule the syringe dictates, which is part of why long-term recombinant GH carries side-effect risks that pulsatile secretagogues, at least in theory, don't.

In conscious swine the dose-response was clean: ED₅₀ of 2.3 nmol/kg, maximum GH release around 65 ng/mL ^[8]. Saturable, predictable pharmacology. Whether it behaves the same way in humans across long-term use is exactly the question the literature hasn't answered.

This is the cleanest piece of the ipamorelin story, so it's worth getting right.

GHRP-6, the original peptide in the family, releases GH effectively but also stimulates appetite hard (via the same ghrelin pathway) and pushes cortisol and prolactin upward. GHRP-2 is more potent at GH release but carries similar cortisol and ACTH co-secretion. For research purposes that's manageable. For long-term clinical use, cortisol elevation is the kind of thing that compounds badly: disrupted sleep, insulin resistance, mood effects, blood pressure drift.

Ipamorelin's design largely sidestepped that. In Raun's 1998 work, even at doses well above what was needed to maximize GH release, there was no real elevation in ACTH, cortisol, prolactin, FSH, LH, or TSH. The mechanism appears to be that GHRP-2 and GHRP-6 hit non-GHSR-1a pathways that ipamorelin doesn't engage. Same GH effect, cleaner downstream profile.

The clinical implication is straightforward, at least on paper: if you're going to stimulate pulsatile GH release, you'd rather do it without raising the stress hormone in parallel. Whether that selectivity translates into meaningfully different long-term outcomes in humans is, again, untested.

This section should reset expectations.

The preclinical literature is genuinely encouraging. In adult female rats, subcutaneous ipamorelin over several weeks produced dose-dependent increases in longitudinal bone growth and body weight gain. Other rodent work showed increased cortical bone mineral density and periosteal bone formation. In diet-induced obese rats, ipamorelin reduced fat mass while preserving lean body mass at magnitudes comparable to recombinant GH. In a 2024 ferret model, it blunted cisplatin-induced weight loss ^[9].

That's a coherent preclinical signal across bone and body composition.

The human literature is two studies and a discontinued trial.

The first human study, published in 1999, was a PK/PD dose-escalation in eight healthy male volunteers per dose group across five dose levels, IV infusion over fifteen minutes ^[10]. It defined the basic pharmacokinetic parameters: EC₅₀ around 214 nmol/L, maximal GH production rate around 694 mIU/L/h, half-life about two hours ^[11]. Inter-individual variability in the pharmacodynamic response exceeded the pharmacokinetic variability, which is a polite way of saying that different people's pituitaries responded quite differently to the same blood concentration. Useful data. Not an efficacy trial.

The second was a Phase II randomized, double-blind, placebo-controlled trial in 117 patients undergoing bowel resection, testing whether IV ipamorelin at 0.03 mg/kg twice daily could shorten postoperative ileus ^[12]. The primary endpoint was time to first tolerated solid meal. Ipamorelin: 25.3 hours. Placebo: 32.6 hours. The numerical gap was real. The p-value was 0.15 ^[13].

Not statistically real. Trial discontinued.

That's the entire body of controlled human efficacy data for ipamorelin. One PK study and one negative Phase II.

Every body composition claim, every muscle-gain claim, every recovery and anti-aging claim circulating in the wellness ecosystem is extrapolated from rodents, from mechanistic plausibility, or from anecdote. Several recent narrative reviews in Translational Andrology and Urology, the American Journal of Sports Medicine, Sports Medicine, and Frontiers in Aging reach the same conclusion using slightly different words: the preclinical signal is interesting, and the human clinical data is essentially absent.

The pairing is everywhere in the peptide literature aimed at consumers, and the mechanistic argument behind it is genuinely sound. Whether the clinical case has been made is another matter.

CJC-1295 is a GHRH analog. It binds the GHRH receptor on somatotrophs and stimulates GH release through the Gs-protein/cAMP pathway ^[14]. Ipamorelin binds GHSR-1a and stimulates GH release through the calcium/PKC pathway. Two receptors, two intracellular cascades, both converging on GH secretion. When you activate both at once, you get more GH than either alone. This was shown in mechanistic work on GHRH-plus-GHRP co-administration by Veldhuis and Bowers in 2009 ^[15], and the principle is well-established at the level of pituitary physiology.

The framing in protocols is usually "pulse and sustain." Ipamorelin produces the acute pulse. CJC-1295, depending on whether it has the DAC modification, raises baseline GHRH tone over hours to days.

The catch: no published human RCT has tested this specific combination for any clinical endpoint. Body composition, recovery, sleep quality, IGF-1 trajectories over months, none of it has been characterized in a controlled trial of CJC-1295 plus ipamorelin together. The mechanistic logic is sound. The clinical validation is missing.

Short answer: very little, at the level of human controlled trials.

What the animal data supports, with caveats about species extrapolation: increased longitudinal bone growth in growing rats, increased cortical bone density, fat-mass reduction with lean-mass preservation in obese rat models, and blunting of cisplatin-induced anorexia in ferrets. These are real findings in their own contexts.

What the human data supports: a measurable, dose-dependent GH pulse following IV administration, with the selectivity profile (no real cortisol, ACTH, or prolactin elevation) preserved in the small healthy-volunteer studies.

What the human data doesn't support: muscle gain, fat loss, improved body composition, anti-aging effects, sleep improvement, injury recovery acceleration, bone density improvement, or any of the longevity claims that dominate ipamorelin marketing. The trials that would establish these effects haven't been done.

Worth noting: GH itself, even when elevated in pulses, has to translate into sustained IGF-1 elevation to drive most of the downstream anabolic effects people are actually seeking. An early rat study found real bone growth from ipamorelin, which is interesting biology and also a reminder that GH release and clinically meaningful anabolic effect are not the same thing.

The IV Phase II trial in postoperative ileus patients reported treatment-emergent adverse events in 87.5% of the ipamorelin group versus 94.8% of placebo ^[16]. That comparison reads reassuring on its surface, but the trial was small, the patient population was recovering from major abdominal surgery, and the study wasn't powered for safety characterization.

The harder signal sits in the FDA's regulatory rationale. When the agency added ipamorelin to Category 2 of its compounding bulk substances list, it cited a specific study identifying serious adverse events, including death, when ipamorelin was administered IV for improving gastric motility. The FDA also flagged immunogenicity concerns related to peptide aggregation and impurities for certain routes of administration, plus the analytical complexity introduced by the unnatural amino acids in the sequence (Aib, D-2-Nal, D-Phe) that complicate quality control and impurity profiling.

The FAERS database, which captures spontaneous reports and doesn't establish causality, shows reports of chronic kidney disease and drug ineffectiveness tied to ipamorelin. FAERS data is notoriously difficult to interpret without knowing co-administered drugs, indication, and route. It's a signal worth knowing about, not a conclusion.

What hasn't been characterized in humans: long-term effects on glucose regulation. GH is counter-regulatory to insulin, and chronic GH elevation produces insulin resistance. Whether pulsatile GH release from a secretagogue does the same thing at the same magnitude over months or years is unknown.

The selectivity advantage is real. The long-term safety story isn't written.

Ipamorelin is not FDA-approved for any therapeutic indication ^[17]. It never has been.

The compounding question is where things get interesting. For years, ipamorelin moved through the U.S. market via 503A compounding pharmacies (patient-specific preparations) and 503B outsourcing facilities. That stopped, mostly, in September 2023, when the FDA placed ipamorelin in Category 2 of its interim policy on bulk substances. Category 2 means the agency has identified real safety risks and the substance is ineligible for compounding while under review.

Industry pushed back. In late 2024, following legal challenges from compounding-pharmacy trade groups, the FDA reached a settlement: the agency agreed to stop classifying these peptides unilaterally and instead submit them to the Pharmacy Compounding Advisory Committee through proper notice-and-comment rulemaking. PCAC review for ipamorelin, CJC-1295, Thymosin Alpha-1, and AOD-9604 was scheduled ^[18].

Following that settlement, FDA removed ipamorelin from Category 2 in 2024 (alongside CJC-1295, AOD-9604, thymosin alpha-1, and Selank) to evaluate it through PCAC rather than by unilateral classification. As of mid-2026 ipamorelin has not been added to the 503A Bulks List, and it was not among the peptides on the FDA's July 23–24, 2026 PCAC agenda, which covered BPC-157, TB-500, KPV, MOTs-C, DSIP (emideltide), Semax, and Epitalon ^[19]. Until FDA adds it to the 503A Bulks List, there is still no affirmative 503A pathway for compounding ipamorelin for human use. Products labeled "research use only" or "not for human consumption" don't satisfy compounding requirements regardless of their packaging language.

No major international regulator (MHRA, EMA, TGA, Health Canada) has granted ipamorelin a marketing authorization ^[20].

In the strict sense, under U.S. law in mid-2026, there's no compliant pathway for human ipamorelin use. The drug isn't approved. Compounding for human administration isn't currently permissible. The legal status could shift after PCAC review, or it could not.

In the research literature, the populations theorized or studied as possible candidates include adult GH deficiency (the original therapeutic frame), hypogonadal males being evaluated for body-composition support, postoperative ileus patients (the Phase II indication that didn't reach significance), and cachexia or chemotherapy-induced anorexia contexts where the ferret data hints at relevance.

The populations where evidence is actively absent: healthy adults seeking body recomposition, aging adults pursuing longevity protocols, athletes pursuing recovery, and anyone using ipamorelin as a wellness intervention rather than for a specific characterized indication. The marketing in these categories has run far ahead of the clinical evidence supporting it.

Anyone with a history of diabetes, insulin resistance, or active malignancy sits in the explicitly cautious zone. GH biology and active cancer don't mix well. The counter-regulatory effects on glucose are well-described for GH itself, and the long-term endocrine consequences of pulsatile GH secretagogue use in healthy adults haven't been studied at the duration most users would actually want them studied at.

The selectivity story is the strongest part of ipamorelin's case. It releases GH without dragging cortisol, prolactin, and ACTH up alongside it, and that's a real pharmacological advantage over the earlier GHRPs, well-characterized in preclinical work.

The clinical story is the weakest part. One PK study in eight healthy men per dose level. One negative Phase II trial in 117 surgical patients. That's the entire human controlled-trial database. Every body composition, muscle, bone, sleep, recovery, and anti-aging claim circulating about ipamorelin is extrapolated from animals, from mechanistic plausibility, or from anecdote.

The CJC-1295 combination is mechanistically coherent and clinically uncharacterized. No human RCT has tested the pairing.

The regulatory ground is moving. Removed from Category 2 in 2024, still not on the 503A Bulks List, and not among the peptides on the July 2026 PCAC agenda — its status is unresolved rather than settled. The legal compounding picture could look meaningfully different in either direction once FDA acts on the Bulks List.

What would genuinely move the field: a properly powered human trial of pulsatile ipamorelin dosing, subcutaneous (the route most users would actually take), measuring IGF-1 trajectory, body composition by DEXA, glucose tolerance, and sleep architecture over at least six months in healthy adults. That trial doesn't exist. Until it does, ipamorelin sits in the category of compounds with elegant mechanism, encouraging animal data, and a clinical evidence base too thin to support the claims being made about it.

The pharmacology is real. The marketing is mostly a hypothesis.